3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
121
Lung Neoplasms
49
Triple Negative Breast Neoplasms
35
Breast Neoplasms
33
Small Cell Lung Carcinoma
29
Squamous Cell Carcinoma of Head and Neck
24
Ovarian Neoplasms
24
Neoplasm Metastasis
21
Fallopian Tube Neoplasms
19
Endometrial Neoplasms
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
15
Head and Neck Neoplasms
12
Colorectal Neoplasms
11
Carcinoma
10
Oropharyngeal Neoplasms
9
Esophageal Neoplasms
9
Urinary Bladder Neoplasms
8
Prostatic Neoplasms
8
Carcinoma, Transitional Cell
8
Pancreatic Neoplasms
7
Carcinoma, Squamous Cell
7
Carcinoma, Ovarian Epithelial
6
Adenocarcinoma of Lung
6
Uterine Cervical Neoplasms
5
Mouth Neoplasms
5
Mesothelioma
5
Lung Diseases
5
Laryngeal Neoplasms
5
Respiratory Tract Neoplasms
4
Interventions
pembrolizumab
4
enfortumab vedotin
3
Gemcitabine
3
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
testosterone 17 beta-cypionate
1
temsirolimus
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
dodecyl maltoside
1
Valproic Acid
1
Testosterone Propionate
1
Sunitinib
1
Standard of Care
1
Sirolimus
1
Ringer's acetate
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Etoposide
1
Doxycycline
1
Disulfides
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Carboplatin
×
90 days
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA